title: Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
abstract: Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 to 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE) ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (less than or equal to grade II) in 24 patients with chief side effects being chills (80% of patients), fever (70%), malaise (60%), and nausea (55%). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8 degrees C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P less than .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, beta 2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1 beta were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-infused technetium-99 (99mTc)-labeled liposomes containing MTP-PE in four patients was biphasic; gamma camera scans revealed uptake of radiolabel in liver, spleen, lung, nasopharynx, thyroid gland, and tumor (two patients). No objective tumor regression was seen. In view of its definite immunobiologic activity and lack of major toxicity, additional phase II and adjuvant trials of L-MTP-PE are warranted.
authors: Department of Clinical Immunology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors: J L
authors: JL
authors: Murray
authors: E S
authors: ES
authors: Kleinerman
authors: J E
authors: JE
authors: Cunningham
authors: J R
authors: JR
authors: Tatom
authors: K
authors: K
authors: Andrejcio
authors: J
authors: J
authors: Lepe-Zuniga
authors: L M
authors: LM
authors: Lamki
authors: M G
authors: MG
authors: Rosenblum
authors: H
authors: H
authors: Frost
authors: J U
authors: JU
authors: Gutterman
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000031:analogs & derivatives; D000209:Acute-Phase Proteins / Q000378:metabolism; D000230:Adenocarcinoma / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006801:Humans; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods; D007375:Interleukin-1 / Q000097:blood; D007958:Leukocyte Count; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D010714:Phosphatidylethanolamines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D012882:Skin Tests; D014018:Tissue Distribution
chemical_list: D000209:Acute-Phase Proteins; D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D008081:Liposomes; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine